{"count": 8, "results": [{"_id": "34281285", "pmid": 34281285, "pmcid": "PMC8269365", "title": "Metformin as a Treatment Strategy for Sjogren's Syndrome", "journal": "Int J Mol Sci", "authors": ["Kim J", "Kim YS", "Park SH"], "date": "2021-07-05T00:00:00Z", "doi": "10.3390/ijms22137231", "meta_date_publication": "2021 Jul 5", "meta_volume": "22", "meta_issue": "13", "meta_pages": "", "score": 50280.76, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ as a Treatment Strategy for @<m>DISEASE_Sjogren's_Syndrome</m> @DISEASE_MESH:D012859 @@@Sjogren's Syndrome@@@", "citations": {"NLM": "Kim J, Kim YS, Park SH. Metformin as a Treatment Strategy for Sjogren's Syndrome Int J Mol Sci. 2021 Jul 5;22(13):. PMID: 34281285", "BibTeX": "@article{34281285, title={Metformin as a Treatment Strategy for Sjogren's Syndrome}, author={Kim J and Kim YS and Park SH}, journal={Int J Mol Sci}, volume={22}, number={13}}"}}, {"_id": "35096887", "pmid": 35096887, "pmcid": "PMC8790021", "title": "Metformin Use Was Associated With Reduced Risk of Incidental Sjogren's Syndrome in Patients With Type 2 Diabetes: A Population-Based Cohort Study", "journal": "Front Med (Lausanne)", "authors": ["Wang CY", "Lai JN", "Liu CH", "Hu KC", "Sheu KL", "Wei JC"], "date": "2022-01-12T00:00:00Z", "doi": "10.3389/fmed.2021.796615", "meta_date_publication": "2021", "meta_volume": "8", "meta_issue": "", "meta_pages": "796615", "score": 50273.76, "text_hl": "But the effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on incidental @<m>DISEASE_Sjogren's_Syndrome</m> @DISEASE_MESH:D012859 @@@Sjogren's syndrome@@@ is unknown. ", "citations": {"NLM": "Wang CY, Lai JN, Liu CH, Hu KC, Sheu KL, Wei JC. Metformin Use Was Associated With Reduced Risk of Incidental Sjogren's Syndrome in Patients With Type 2 Diabetes: A Population-Based Cohort Study Front Med (Lausanne). 2021;8():796615. PMID: 35096887", "BibTeX": "@article{35096887, title={Metformin Use Was Associated With Reduced Risk of Incidental Sjogren's Syndrome in Patients With Type 2 Diabetes: A Population-Based Cohort Study}, author={Wang CY and Lai JN and Liu CH and Hu KC and Sheu KL and Wei JC}, journal={Front Med (Lausanne)}, volume={8}, pages={796615}}"}}, {"_id": "34879473", "pmid": 34879473, "pmcid": "PMC8747910", "title": "Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease", "journal": "Korean J Intern Med", "authors": ["Kim JW", "Choe JY", "Park SH"], "date": "2022-01-01T00:00:00Z", "doi": "10.3904/kjim.2021.363", "meta_date_publication": "2022 Jan", "meta_volume": "37", "meta_issue": "1", "meta_pages": "13-26", "score": 50263.68, "text_hl": "The efficacy of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has been investigated in preclinical and clinical studies on @DISEASE_Arthritis_Rheumatoid @DISEASE_MESH:D001172 @@@rheumatoid arthritis@@@, @DISEASE_Osteoarthritis @DISEASE_MESH:D010003 @@@osteoarthritis@@@, @DISEASE_Lupus_Erythematosus_Systemic @DISEASE_MESH:D008180 @@@systemic lupus erythematosus@@@, @<m>DISEASE_Sjogren's_Syndrome</m> @DISEASE_MESH:D012859 @@@Sjogren's syndrome@@@, @DISEASE_Scleroderma_Systemic @DISEASE_MESH:D012595 @@@scleroderma@@@, @DISEASE_Spondylitis_Ankylosing @DISEASE_MESH:D013167 @@@ankylosing spondylitis@@@, and @DISEASE_Gout @DISEASE_MESH:D006073 @@@gout@@@. ", "citations": {"NLM": "Kim JW, Choe JY, Park SH. Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease Korean J Intern Med. 2022 Jan;37(1):13-26. PMID: 34879473", "BibTeX": "@article{34879473, title={Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease}, author={Kim JW and Choe JY and Park SH}, journal={Korean J Intern Med}, volume={37}, number={1}, pages={13-26}}"}}, {"_id": "40854596", "pmid": 40854596, "title": "Exploring MHC class II I-Ab blockade as a potential treatment for Sjogren's disease in the mouse model.", "journal": "Immunohorizons", "authors": ["Voigt A", "Gupta S", "Shen Y", "Glenton P", "Li D", "Ostrov D", "Bhattacharyya I", "Nguyen CQ"], "date": "2025-08-25T00:00:00Z", "doi": "10.1093/immhor/vlaf030", "meta_date_publication": "2025 Aug 25", "meta_volume": "9", "meta_issue": "9", "meta_pages": "", "score": 50261.79, "text_hl": "T cell receptor transductant assays revealed that CHPE and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ exert their therapeutic effects through antigen-specific pathways, inhibiting T cell responses to @<m>DISEASE_Sjogren's_Syndrome</m> @DISEASE_MESH:D012859 @@@SjD@@@-associated autoantigens. ", "citations": {"NLM": "Voigt A, Gupta S, Shen Y, Glenton P, Li D, Ostrov D, Bhattacharyya I, Nguyen CQ. Exploring MHC class II I-Ab blockade as a potential treatment for Sjogren's disease in the mouse model. Immunohorizons. 2025 Aug 25;9(9):. PMID: 40854596", "BibTeX": "@article{40854596, title={Exploring MHC class II I-Ab blockade as a potential treatment for Sjogren's disease in the mouse model.}, author={Voigt A and Gupta S and Shen Y and Glenton P and Li D and Ostrov D and Bhattacharyya I and Nguyen CQ}, journal={Immunohorizons}, volume={9}, number={9}}"}}, {"_id": "37711153", "pmid": 37711153, "pmcid": "PMC10497794", "title": "Metformin-induced activation of Ca2+ signaling prevents immune infiltration/pathology in Sjogren's syndrome-prone mouse models", "journal": "J Transl Autoimmun", "authors": ["Nascimento Da Conceicao V", "Sun Y", "Chai X", "Ambrus JL", "Mishra BB", "Singh BB"], "date": "2023-09-09T00:00:00Z", "doi": "10.1016/j.jtauto.2023.100210", "meta_date_publication": "2023 Dec", "meta_volume": "7", "meta_issue": "", "meta_pages": "100210", "score": 50259.066, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@-induced activation of Ca2+ signaling prevents immune infiltration/pathology in @<m>DISEASE_Sjogren's_Syndrome</m> @DISEASE_MESH:D012859 @@@Sjogren's syndrome@@@-prone @SPECIES_10090 @@@mouse@@@ models", "citations": {"NLM": "Nascimento Da Conceicao V, Sun Y, Chai X, Ambrus JL, Mishra BB, Singh BB. Metformin-induced activation of Ca2+ signaling prevents immune infiltration/pathology in Sjogren's syndrome-prone mouse models J Transl Autoimmun. 2023 Dec;7():100210. PMID: 37711153", "BibTeX": "@article{37711153, title={Metformin-induced activation of Ca2+ signaling prevents immune infiltration/pathology in Sjogren's syndrome-prone mouse models}, author={Nascimento Da Conceicao V and Sun Y and Chai X and Ambrus JL and Mishra BB and Singh BB}, journal={J Transl Autoimmun}, volume={7}, pages={100210}}"}}, {"_id": "36155926", "pmid": 36155926, "title": "mTORC1-GLUT1-mediated glucose metabolism drives hyperactivation of B cells in primary Sjogren's syndrome.", "journal": "Immunology", "authors": ["Luo X", "Wu X", "Wang A", "Chen Y", "Peng Y", "Deng C", "Zhao L", "Yang H", "Zhou J", "Peng L", "Wu Q", "Li M", "Zhao Y", "Zeng X", "Zhang W", "Fei Y"], "date": "2022-09-25T00:00:00Z", "doi": "10.1111/imm.13580", "meta_date_publication": "2022 Sep 25", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50248.043, "text_hl": "Both @CHEMICAL_Deoxyglucose @CHEMICAL_MESH:D003847 @@@2-DG@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ inhibited the proliferation, formation of plasma/plasmablasts and decreased the IgG and IgM levels in the supernatants of B cells from @<m>DISEASE_Sjogren's_Syndrome</m> @DISEASE_MESH:D012859 @@@pSS@@@ @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Luo X, Wu X, Wang A, Chen Y, Peng Y, Deng C, Zhao L, Yang H, Zhou J, Peng L, Wu Q, Li M, Zhao Y, Zeng X, Zhang W, Fei Y. mTORC1-GLUT1-mediated glucose metabolism drives hyperactivation of B cells in primary Sjogren's syndrome. Immunology. 2022 Sep 25;():. PMID: 36155926", "BibTeX": "@article{36155926, title={mTORC1-GLUT1-mediated glucose metabolism drives hyperactivation of B cells in primary Sjogren's syndrome.}, author={Luo X and Wu X and Wang A and Chen Y and Peng Y and Deng C and Zhao L and Yang H and Zhou J and Peng L and Wu Q and Li M and Zhao Y and Zeng X and Zhang W and Fei Y}, journal={Immunology}}"}}, {"_id": "34987398", "pmid": 34987398, "pmcid": "PMC8722737", "title": "Artesunate Combined With Metformin Ameliorate on Diabetes-Induced Xerostomia by Mitigating Superior Salivatory Nucleus and Salivary Glands Injury in Type 2 Diabetic Rats via the PI3K/AKT Pathway", "journal": "Front Pharmacol", "authors": ["Zhang S", "Li J", "Nong X", "Zhan Y", "Xu J", "Zhao D", "Ma C", "Wang Y", "Li Y", "Li Z", "Li J"], "date": "2021-12-20T00:00:00Z", "doi": "10.3389/fphar.2021.774674", "meta_date_publication": "2021", "meta_volume": "12", "meta_issue": "", "meta_pages": "774674", "score": 50231.71, "text_hl": "Recent studies have reported that @CHEMICAL_Artesunate @CHEMICAL_MESH:D000077332 @@@artesunate@@@ (ART) and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (@GENE_MET @GENE_24553 @@@Met@@@) improve @DISEASE_Adrenal_Insufficiency @DISEASE_MESH:D000309 @@@salivary gland (SG) hypofunction@@@ in @SPECIES_10090 @@@murine@@@ @<m>DISEASE_Sjogren's_Syndrome</m> @DISEASE_MESH:D012859 @@@Sjogren's syndrome@@@. ", "citations": {"NLM": "Zhang S, Li J, Nong X, Zhan Y, Xu J, Zhao D, Ma C, Wang Y, Li Y, Li Z, Li J. Artesunate Combined With Metformin Ameliorate on Diabetes-Induced Xerostomia by Mitigating Superior Salivatory Nucleus and Salivary Glands Injury in Type 2 Diabetic Rats via the PI3K/AKT Pathway Front Pharmacol. 2021;12():774674. PMID: 34987398", "BibTeX": "@article{34987398, title={Artesunate Combined With Metformin Ameliorate on Diabetes-Induced Xerostomia by Mitigating Superior Salivatory Nucleus and Salivary Glands Injury in Type 2 Diabetic Rats via the PI3K/AKT Pathway}, author={Zhang S and Li J and Nong X and Zhan Y and Xu J and Zhao D and Ma C and Wang Y and Li Y and Li Z and Li J}, journal={Front Pharmacol}, volume={12}, pages={774674}}"}}, {"_id": "31164166", "pmid": 31164166, "pmcid": "PMC6549273", "title": "Metformin improves salivary gland inflammation and hypofunction in murine Sjogren's syndrome", "journal": "Arthritis Res Ther", "authors": ["Kim JW", "Kim SM", "Park JS", "Hwang SH", "Choi J", "Jung KA", "Ryu JG", "Lee SY", "Kwok SK", "Cho ML", "Park SH"], "date": "2019-06-04T00:00:00Z", "doi": "10.1186/s13075-019-1904-0", "meta_date_publication": "2019 Jun 4", "meta_volume": "21", "meta_issue": "1", "meta_pages": "136", "score": 50093.49, "text_hl": "Therefore, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ may be a potential therapeutic for @<m>DISEASE_Sjogren's_Syndrome</m> @DISEASE_MESH:D012859 @@@SS@@@.", "citations": {"NLM": "Kim JW, Kim SM, Park JS, Hwang SH, Choi J, Jung KA, Ryu JG, Lee SY, Kwok SK, Cho ML, Park SH. Metformin improves salivary gland inflammation and hypofunction in murine Sjogren's syndrome Arthritis Res Ther. 2019 Jun 4;21(1):136. PMID: 31164166", "BibTeX": "@article{31164166, title={Metformin improves salivary gland inflammation and hypofunction in murine Sjogren's syndrome}, author={Kim JW and Kim SM and Park JS and Hwang SH and Choi J and Jung KA and Ryu JG and Lee SY and Kwok SK and Cho ML and Park SH}, journal={Arthritis Res Ther}, volume={21}, number={1}, pages={136}}"}}]}